- Home
- IMVT vs RARE Comparison
IMVT vs RARE Comparison
Compare IMVT & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMVT
- RARE
- Stock Information
- Founded
- IMVT 2018
- RARE 2010
- Country
- IMVT United States
- RARE United States
- Employees
- IMVT N/A
- RARE N/A
- Industry
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- IMVT Health Care
- RARE Health Care
- Exchange
- IMVT Nasdaq
- RARE Nasdaq
- Market Cap
- IMVT 2.7B
- RARE 2.6B
- IPO Year
- IMVT N/A
- RARE 2014
- Fundamental
- Price
- IMVT $15.24
- RARE $29.78
- Analyst Decision
- IMVT Buy
- RARE Strong Buy
- Analyst Count
- IMVT 11
- RARE 14
- Target Price
- IMVT $35.88
- RARE $86.64
- AVG Volume (30 Days)
- IMVT 1.2M
- RARE 1.7M
- Earning Date
- IMVT 08-11-2025
- RARE 08-05-2025
- Dividend Yield
- IMVT N/A
- RARE N/A
- EPS Growth
- IMVT N/A
- RARE N/A
- EPS
- IMVT N/A
- RARE N/A
- Revenue
- IMVT N/A
- RARE $610,159,000.00
- Revenue This Year
- IMVT N/A
- RARE $18.70
- Revenue Next Year
- IMVT N/A
- RARE $26.76
- P/E Ratio
- IMVT N/A
- RARE N/A
- Revenue Growth
- IMVT N/A
- RARE 26.77
- 52 Week Low
- IMVT $12.72
- RARE $25.81
- 52 Week High
- IMVT $34.47
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- IMVT 43.58
- RARE 52.44
- Support Level
- IMVT $14.50
- RARE $28.85
- Resistance Level
- IMVT $15.52
- RARE $30.10
- Average True Range (ATR)
- IMVT 0.69
- RARE 0.97
- MACD
- IMVT -0.06
- RARE 0.44
- Stochastic Oscillator
- IMVT 41.16
- RARE 83.80
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.